Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Vaccines (Basel) ; 12(9)2024 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-39340050

RESUMEN

Rotavirus considerably threatens global health, particularly for children <5 years. Current, licensed oral attenuated vaccine formulations have limitations including insufficient efficacy in children in low- and middle-income countries, warranting urgent development of novel vaccines with improved efficacy and safety profiles. Herein, we present a novel approach utilizing an encapsulin (ENC) nanoparticle (NP)-based non-replicating rotavirus vaccine. ENC, originating from bacteria, offers a self-assembling scaffold that displays rotavirus VP8* antigens on its surface. To enhance the correct folding and soluble expression of monomeric antigens and their subsequent assembly into NP, we adopted an RNA-interacting domain (RID) of mammalian transfer RNA synthetase as an expression tag fused to the N-terminus of the ENC-VP8* fusion protein. Using the RID-ENC-VP8* tripartite modular design, insertion of linkers of appropriate length and sequence and the universal T cell epitope P2 remarkably improved the production yield and immunogenicity. Cleavage of the RID rendered a homogenous assembly of ENC-P2-VP8* into protein NPs. Immunization with ENC-P2-VP8* induced markedly higher levels of VP8*-specific antibodies and virus neutralization titers in mice than those induced by P2-VP8* without ENC. Altogether, these results highlight the potential of the designed ENC NP-based rotavirus vaccine as an effective strategy against rotavirus disease to address global health challenges.

2.
Int J Infect Dis ; 138: 73-80, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37944586

RESUMEN

OBJECTIVE: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. METHODS: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. RESULTS: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the "early" period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the "late" period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). CONCLUSION: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Humanos , Vacunas contra la COVID-19/efectos adversos , Liposomas , COVID-19/prevención & control , Anticuerpos Neutralizantes , Vacunas de Subunidad , República de Corea , Anticuerpos Antivirales
3.
Forensic Sci Int ; 257: 403-408, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26555502

RESUMEN

In order to study fingerprinting in the field of forensic science, it is very important to have two or more latent fingerprints with identical chemical composition and intensity. However, it is impossible to obtain identical fingerprints, in reality, because fingerprinting comes out slightly differently every time. A previous research study had proposed an artificial fingerprint creation method in which inkjet ink was replaced with amino acids and sodium chloride solution: the components of human sweat. But, this method had some drawbacks: divalent cations were not added while formulating the artificial sweat solution, and diluted solutions were used for creating weakly deposited latent fingerprint. In this study, a method was developed for overcoming the drawbacks of the methods used in the previous study. Several divalent cations were added in this study because the amino acid-ninhydrin (or some of its analogues) complex is known to react with divalent cations to produce a photoluminescent product; and, similarly, the amino acid-1,2-indanedione complex is known to be catalyzed by a small amount of zinc ions to produce a highly photoluminescent product. Also, in this study, a new technique was developed which enables to adjust the intensity when printing the latent fingerprint patterns. In this method, image processing software is used to control the intensity of the master fingerprint patterns, which adjusts the printing intensity of the latent fingerprints. This new method opened the way to produce a more realistic artificial fingerprint in various strengths with one artificial sweat working solution.


Asunto(s)
Periféricos de Computador , Dermatoglifia , Procesamiento de Imagen Asistido por Computador , Tinta , Sudor/química , Compuestos Aza , Humanos , Indanos , Indicadores y Reactivos , Yodo , Luminiscencia , Ninhidrina , Reproducibilidad de los Resultados , Nitrato de Plata , Zinc
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...